Bookmark

Add to MyYahoo RSS

Vicept Therapeutics News

News on Vicept Therapeutics (Ticker: AGN) continually updated from thousands of sources around the net.

Yesterday | Customer Interaction Solutions

Allergan Comments on Pershing Square's Definitive Proxy Solicitation

At the Special Meeting, if called, Allergan stockholders would be asked to remove a majority of the Company's existing directors in connection with Valeant Pharmaceuticals International, Inc.'s unsolicited exchange offer to acquire all outstanding common shares of Allergan for 0.83 shares of Valeant common stock and $72.00 in cash, or subject to ... (more)

Comment?

Related Topix: Allergan, Biotech, Marketing

Friday | Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Curse Inc. and Hi-Rez Studios Announce Integration Between Curse Inc.'s Curse Voice, and Hi-Rez Studios' Poplar Game, SMITE )--Curse Inc. a leading video game media and technology company, and Hi-Rez Studios, creators of the popular online video game, SMITE, announced today the ... )--Delek Logistics Partners, LP today announced that the ... (more)

Comment?

Related Topix: Hi-Rez Studios, SMITE, Video Games, Allergan, Biotech, Energy, Delek US, Arthur JGallagher , Insurance, Financial Services

Mon Jul 07, 2014

Insider Monkey

Hedge Fund News: Jim Simons, Feroz Dewan & Soros Fund Management

Simonses give $50 million to Cold Spring Harbor lab Long Island hedge-fund investor James Simons and his wife have given $50 million to the Cold Spring Harbor Laboratory to establish a center that uses quantitative tools to understand fundamental biology, including studying disease and illness, the lab said Monday.

Comment?

Related Topix: Soros Fund Management, Financial Services, Investment Services, Cold Spring Harbor, NY, Mathematics, Science, Allergan, Biotech

Sat Jul 05, 2014

The Motley Fool

This Week in Biotech: Allergan Three-Peats in a Bad Way While Agenus Impresses

With the SPDR S&P Biotech Index up 45% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector.

Comment?

Related Topix: Allergan, Healthcare Law, Law, Food and Drug Administration, Lymphoma, Health

Wed Jul 02, 2014

BioSpace

Top 10 Monthly News For June 2014

July 2, 2014 Top 10 Monthly News For June 2014 A happy summer to all of you as we approach July 4th with thoughts of burgers, hot dogs, and beautiful fireworks in the sky.

Comment?

Related Topix: Allergan, Movetis, Foldrx Pharmaceuticals, Cambridge, MA

Tue Jul 01, 2014

Insider Monkey

Bill Ackman's Pershing Square Settles Litigation With Allergan Inc.

Pershing Square , managed by Bill Ackman , revealed in a new filing with the U.S. Securities and Exchange Commission that it has settled a lawsuit with Allergan Inc. .

Comment?

Related Topix: Allergan, Biotech, US Securities and Exchange Commission, Financial Services

Insider Monkey

Hedge Fund Highlights: John Paulson, Bill Miller & Bridgewater Associates

Paulson's Credit Opportunities fund up 6.6 percent ytd to end-May: source Hedge fund manager John Paulson 's credit opportunities and merger arbitrage funds were up 6.6 percent and 3.3 percent year-to-date through the end of May, respectively, easily surpassing their benchmarks, according to an investor in attendance at Paulson & Co's recent ... (more)

Comment?

Related Topix: Reuters, Allergan, Biotech, Mutual Funds, Personal Finance, Blackstone Group, Advertising

Mon Jun 30, 2014

Insider Monkey

Hedge Fund Highlights: Bill Ackman, Philip Falcone & Paul Singer

Allergan Poison Pill Won't Be Triggered by Pershing Call Allergan, Inc. agreed with Pershing Square Capital Management LP that a call for a special shareholder meeting to replace part of the drugmaker's board won't trigger a "poison pill" takeover defense.

Comment?

Related Topix: Allergan, Biotech, Irvine, CA, Cable & Satellite, Telecom, DISH Network, Television

Investor's Business Daily

Allergan Announces R&D Pipeline Update and U.S. FDA Approval;...

Receives FDA Approval for OZURDEX A 0.7 mg as Treatment Option for Diabetic Macular Edema in Certain Patients-- IRVINE, Calif.-- -- Allergan, Inc. today announced updates on three of the Company's key R&D pipeline programs, including abicipar pegol , bimatoprost sustained-release implant for glaucoma and SEMPRANAa inhalation aerosol .

Comment?

Related Topix: Allergan, Biotech, Food and Drug Administration, Lumigan, Bimatoprost (generic), Medicine, Glaucoma, Health

Thu Jun 26, 2014

The Motley Fool

Biotech Stocks to Watch Today: Agenus, Allergan and Auxilium Pharmaceuticals

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Agenus .

Comment?

Related Topix: Allergan, Biotech, Auxilium Pharmaceuticals

Insider Monkey

Hedge Fund Highlights: Warren Buffett, John Paulson & Bain Capital

Warren Buffett's BNSF and Canadian Pacific Railway gets U.S. deadline to solve grain backlog Warren Buffett 's BNSF Railway Co.

Comment?

Related Topix: Venture Capital, Emerging Technology, Startups, Bain Capital, Warren Buffett, Transportation, Railroads, Canadian Pacific Railway, Allergan, Biotech

Tue Jun 24, 2014

Vision Monday

Allergan Board Unanimously Rejects Valeanta s Unsolicited Takeover Bid

IRVINE, Calif.-After consulting with its independent financial and legal advisors, the board of Allergan, Inc .

Comment?

Related Topix: Allergan, Biotech, Irvine, CA, Valeant Pharmaceuticals International

Benzinga

#PreMarket Primer: Tuesday, June 24: Pressure On Maliki To Step Down Intensifies

US Secretary of State John Kerry traveled to Baghdad on Monday to pledge the US' "intense" and "sustained" support in Iraq's ongoing crisis.

Comment?

Related Topix: Iraq, World News, Goldman Sachs, Financial Services, Investment Services, Cohen Group, Consulting, Allergan, Biotech

Mon Jun 23, 2014

The Motley Fool

Monday's Top Biotech Stocks to Watch: Rockwell, AbbVie, Shire, Allergan, and Valeant

Vitamin D deficiency is common in dialysis patients, and can cause elevated parathyroid hormone levels which lead to various bone and joint problems.

Comment?

Related Topix: Allergan, Movetis, Dialysis, Medicine, Health, Rocaltrol, Calcitriol (generic), Food and Drug Administration

Business Wire

Allergan Board of Directors Unanimously Rejects Unsolicited Exchange Offer from Valeant

Accordingly, the Board strongly recommends that Allergan stockholders not tender any Allergan shares to Valeant.

Comment?

Related Topix: Allergan, Biotech

Fri Jun 20, 2014

Forbes.com

Shire Soars After Rejecting AbbVie's $46 Billion Inversion Takeover

The potential acquisition is just the latest in a string of 2014 health care merger tries, including Valeant's ongoing pursuit of Allergan , the Abbvie-Shire merger is based on the inversion tax loop hole, in which American countries can avoid US corporate taxes and access overseas profits by reincorporating in the country of their acquisition.

Comment?

Related Topix: Allergan, Biotech, Healthcare Industry

Thu Jun 19, 2014

Vision Monday

Valeant Presses Bid for Allergan with Exchange Offer to Stockholders

LAVAL, Quebec- Valeant Pharmaceuticals International , based here, stepped up its bid to acquire Botox-maker Allergan by announcing Wednesday that it is taking its latest proposal directly to Allergan stockholders.

Comment?

Related Topix: Allergan, Biotech, Valeant Pharmaceuticals International

Wed Jun 18, 2014

Freshnews

Allergan Board of Directors to Review Unsolicited Exchange Offer from Valeant

Allergan, Inc. today commented on Valeant Pharmaceuticals International, Inc.'s unsolicited exchange offer to acquire all outstanding common shares of Allergan.

Comment?

Related Topix: Allergan, Biotech, Securities and Exchange Commission, Corporate / Securities Law, Law, Marketing

Tue Jun 17, 2014

Investor's Business Daily

Valeant shifts takeover tactics

Allergan has rebuffed multiple earlier offers. Valeant Pharmaceuticals' CEO Michael Pearson said that proxies seeking Allergan shareholder support for the bid will be in the mail soon.

Comment?

Related Topix: Allergan, Biotech

GlobeNewswire

Wellness Center USA, Inc. Featured on Mergermarket

Wellness Center USA, Inc. , a healthcare, medical, and technology solutions company, today announced that its wholly owned subsidiary, Psoria-Shield, was recently featured on Mergermarket, the leading provider of forward-looking M&A intelligence and data to M&A professionals and corporates.

Comment?

Related Topix: Medicine, Allergan, Dermatology, Enbrel, Etanercept (generic), Aria Systems

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••